Gustavo Velasquez is an Infectious Disease physician. ClinicalTrials.gov lists 2 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
995 Potrero Avenue
Building 80, 6th Floor, Ward 86
San Francisco, CA 94110
Telephone
628-206-2400Provider last certified this registry record 2 Apr 2026.
Clinical trials
2 registered studies on ClinicalTrials.gov matched to this name. Itemized trial rows, roles and sponsors are part of the full profile. Why? →
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
49.1%Statin38.7%Atorvastatin Calcium100%Part D<11 patientsACE inhibitor10.4%Lisinopril-Hydrochlorothiazide100%Part D<11 patientsGenitourinary & hormones
32.1%alpha-Adrenergic Blocker19.8%Tamsulosin Hcl100%Part D<11 patientsbeta3-Adrenergic Agonist12.3%Gemtesa100%Part D<11 patientsAnti-infectives
18.9%Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor18.9%Triumeq100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
3 NIH research awards on record, funded 2021–2026 per NIH RePORTER. The latest:
- Immunogenetic determinants of response to drug-susceptible tuberculosis treatment
University of California, San Francisco
FY2026$842,888R01AI196019 - A Phase 2C Randomized, Controlled, Open-Label Trial of Novel Shortened Regimens for the Treatment of Isoniazid-Monoresistant TB (IMR-TB)
University of California, San Francisco
FY2024$256,504R34AI179568 - Safety and tolerability of new and repurposed drugs for MDR-TB treatment
University of California, San Francisco
FY2023$197,640K08AI141740
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
Yousef Khader
Jordan University of Science and Technology
Andrew Rambaut
University of Edinburgh
Olayinka Stephen Ilesanmi
University College Hospital
Maysaa El Sayed Zaki
Mansoura University
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”